HOLLIS EDEN PHARMACEUTICALS INC /DE/
HEPHTicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at HOLLIS EDEN PHARMACEUTICALS INC /DE/ (HEPH) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 9 insiders have filed 59 transactions totaling $349.1K in trading activity. The most active insider is Robert W. Weber (Executive), contributing $230.1K across 27 transactions.
HOLLIS EDEN PHARMACEUTICALS INC /DE/ insiders are currently net sellers of HEPH stock, showing bearish sentiment over the past 90 days. Total sales of $265.1K outpace purchases of $84.0K, creating a net outflow of $181.0K.
HOLLIS EDEN PHARMACEUTICALS INC /DE/ has 9 active insiders who have filed SEC Form 4 transactions in the past 90 days. Robert W. Weber (Executive) leads with 27 transactions totaling $230.1K. Brendan Mcdonnell (Executive) follows with 6 transactions worth $148.0K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. HOLLIS EDEN PHARMACEUTICALS INC /DE/'s current score of 24/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.
The most recent insider transaction occurred on Mar 5, 2007, when W. Weber Robert (Executive) disposed of 300 shares at $5.26 per share for $1.6K. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, HEPH insider trading sentiment is currently bearish with an Alignment Score of 24/100. The negative net flow of $181.0K shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like HOLLIS EDEN PHARMACEUTICALS INC /DE/. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At HEPH, we track all Form 4 filings—currently showing 59 transactions from 9 insiders over 90 days.
A 10b5-1 plan allows HOLLIS EDEN PHARMACEUTICALS INC /DE/ executives to pre-schedule stock sales when they don't possess material non-public information. At HEPH, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at HEPH appears discretionary, making insider signals more meaningful.
You can monitor HOLLIS EDEN PHARMACEUTICALS INC /DE/ (HEPH) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 9 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at HOLLIS EDEN PHARMACEUTICALS INC /DE/ (HEPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 9 insiders are actively trading HEPH stock, having executed 59 transactions in the past 90 days. The most active insider is Robert W. Weber (Executive), with 27 transactions totaling $230.1K.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. HOLLIS EDEN PHARMACEUTICALS INC /DE/'s current score of 24/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $84.0K in purchases versus $265.1K in sales over 90 days, resulting in a net flow of -$181.0K.
SEC Form 4 filings are mandatory reports that HOLLIS EDEN PHARMACEUTICALS INC /DE/ insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At HEPH, the most common type is "S" with 41 occurrences. The most recent Form 4 was filed on Mar 5, 2007 by W. Weber Robert.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At HOLLIS EDEN PHARMACEUTICALS INC /DE/, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at HEPH represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for HOLLIS EDEN PHARMACEUTICALS INC /DE/ and 40,000+ other insiders.